Zhaoke Ophthalmology-B (06622) Partners with AFT and Senju to Commercialize BRIMOCHOL™ PF for Presbyopia in Singapore and Vietnam

Stock News

Jan 26

Zhaoke Ophthalmology-B (06622) announced that it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with the leading Asian ophthalmic company Senju Pharmaceutical Co., Ltd. (Senju) to commercialize the product in Vietnam. Zhaoke has granted AFT and Senju exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Senju become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential therapy for correcting the loss of near vision due to presbyopia and is a core asset licensed by the company through its partner Tenpoint Therapeutics, Ltd. (Tenpoint). Tenpoint is a global, commercially-ready biotechnology company developing breakthrough therapies to restore vision in aging eyes. In June 2025, Tenpoint announced that the U.S. FDA had accepted the New Drug Application for this product. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for BRIMOCHOL™ PF, with a review deadline of January 28, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173322734"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173322734\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173322734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173322734","market":"sg","top_or_hot":-1,"title":"Zhaoke Ophthalmology-B (06622) Partners with AFT and Senju to Commercialize BRIMOCHOL™ PF for Presbyopia in Singapore and Vietnam","media":"Stock News","content":"<p>Zhaoke Ophthalmology-B (06622) announced that it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with the leading Asian ophthalmic company Senju Pharmaceutical Co., Ltd. (Senju) to commercialize the product in Vietnam. Zhaoke has granted AFT and Senju exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Senju become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential therapy for correcting the loss of near vision due to presbyopia and is a core asset licensed by the company through its partner Tenpoint Therapeutics, Ltd. (Tenpoint). Tenpoint is a global, commercially-ready biotechnology company developing breakthrough therapies to restore vision in aging eyes. In June 2025, Tenpoint announced that the U.S. FDA had accepted the New Drug Application for this product. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for BRIMOCHOL™ PF, with a review deadline of January 28, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B (06622) Partners with AFT and Senju to Commercialize BRIMOCHOL™ PF for Presbyopia in Singapore and Vietnam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B (06622) Partners with AFT and Senju to Commercialize BRIMOCHOL™ PF for Presbyopia in Singapore and Vietnam\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-26 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhaoke Ophthalmology-B (06622) announced that it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with the leading Asian ophthalmic company Senju Pharmaceutical Co., Ltd. (Senju) to commercialize the product in Vietnam. Zhaoke has granted AFT and Senju exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Senju become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential therapy for correcting the loss of near vision due to presbyopia and is a core asset licensed by the company through its partner Tenpoint Therapeutics, Ltd. (Tenpoint). Tenpoint is a global, commercially-ready biotechnology company developing breakthrough therapies to restore vision in aging eyes. In June 2025, Tenpoint announced that the U.S. FDA had accepted the New Drug Application for this product. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for BRIMOCHOL™ PF, with a review deadline of January 28, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1173322734","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173322734","pubTimestamp":1769417419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhaoke Ophthalmology-B (06622) announced that it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","06622":"兆科眼科-B","BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","AFT":"Apollo Senior Floating Rate Fund"},"translate_title":"兆科眼科-B(06622)与AFT及Senju合作商业化BRIMOCHOL™新加坡和越南的老花眼PF","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1,"AFT":1},"content_text":"Zhaoke Ophthalmology-B (06622) announced that it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with the leading Asian ophthalmic company Senju Pharmaceutical Co., Ltd. (Senju) to commercialize the product in Vietnam. Zhaoke has granted AFT and Senju exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Senju become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential therapy for correcting the loss of near vision due to presbyopia and is a core asset licensed by the company through its partner Tenpoint Therapeutics, Ltd. (Tenpoint). Tenpoint is a global, commercially-ready biotechnology company developing breakthrough therapies to restore vision in aging eyes. In June 2025, Tenpoint announced that the U.S. FDA had accepted the New Drug Application for this product. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for BRIMOCHOL™ PF, with a review deadline of January 28, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}